Myriad Genetics Inc. and Ultima Genomics Inc. join to explore Ultima’s UG 100 sequencing platform and its ppmSeq technology to advance Myriad’s ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its Lab of the Future facility in South San Francisco.
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
Having had the honor and pleasure to lead an NCI-designated cancer center for several years, I would like to share my thoughts on this small yet unique set of institutes and their value to NCI and the nation.
On Nov. 24, 2003, an article in The Boston Globe told the story of a patient’s remarkable response to gefitinib, a drug that had recently been approved by FDA.
Kevin Holcomb will join Northwell Health as chair of the Department of Obstetrics and Gynecology at North Shore University Hospital in Manhasset, Long Island Jewish Medical Center in New Hyde Park, and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale.
Meagan O. O’Neill was named executive director of the Association of Cancer Care Centers. O’Neill will serve as the third executive director and the first woman in the role.
Sir Paul Nurse is the recipient of the 26th Herbert and Maxine Block Memorial Lectureship Award for Distinguished Achievement in Cancer. A geneticist and cell biologist who shared the 2001 Nobel Prize in Physiology or Medicine, Nurse is founding director and chief executive officer of the Francis Crick Institute in London.
NCI has awarded researchers at Washington University School of Medicine in St. Louis a Specialized Programs of Research Excellence grant to spur new strategies to prevent and treat endometrial cancer.
Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.
Qure.ai has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the U.S. market and other countries, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.
